Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory syncytial virus (RSV) vaccine in children.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,